China's Food and Drug Administration is inviting feedback on a new batch of medium- and high-risk medical devices that it intends to exempt from having to undergo local clinical trials. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market.
The new batch –when combined with the devices that are already exempt from undergoing local trials - could result...





